In traditional schedule or dose-schedule finding designs, patients are assumed to receive their assigned dose-schedule combination throughout the trial even though the combination may be found to have an undesirable toxicity profile, which contradicts actual clinical practice. Since no systematic approach exists to optimize intra-patient dose-schedule as-signment, we propose a Phase I clinical trial design that extends existing approaches that optimize dose and schedule solely among patients by incorporating adaptive variations to dose-schedule assignments within patients as the study proceeds. Our design is based on a Bayesian non-mixture cure rate model that incorporates multiple administrations each patient receives with the per-administration dose included as a covariate. Simulations demonstrate that our design identifies safe dose and schedule combinations as well as the traditional method that does not allow for intra-patient dose-schedule reassignments, but with a larger number of patients assigned to safe combinations. 
INTRODUCTION
Traditional Phase I clinical trials seek to identify the maximum-tolerated dose (MTD) among a set of discrete doses by characterizing a patient's outcome as a binary indicator of whether the patient experiences a dose-limiting toxicity (DLT) within a fixed duration of time. The MTD is the dose at which the probability of having a DLT is near a predefined target (usually 0.20-0.40) . A DLT is typically defined as a Grade 3 or higher toxicity (National Cancer Institute 2003) that prevents further treatment of the patient. Of the various methods for traditional Phase I trials, the Continual Reassessment Method (CRM) of O'Quigley, Pepe, and Fisher (1990) is one of the most popular model-based designs that update the MTD estimate adaptively. Numerous extensions to the CRM have been proposed, including the Time-to-Event CRM (TITE-CRM) of Cheung and Chappell (2000) to account for incomplete follow-up of patients and the later generalization of Braun (2005) to adapt the TITE-CRM for early-and late-onset DLTs.
Contrary to conventional Phase I designs seeking to find the MTD with a fixed schedule of administrations, new designs have been proposed to identify the maximum-tolerated schedule (MTS) among a set of pre-specified schedules when the per-administration dose is fixed. Schedule-finding studies are especially important when the agent is given at a fixed dose repeatedly in a sequence of administrations and long-term cumulative toxicities are of interest. Braun, Zheng, and Thall (2004) proposed an innovative design to model the time to toxicity rather than a binary outcome using a triangular hazard model for each administration to determine the MTS. Liu and Braun (2009) developed a more flexible model for the cumulative hazard of a DLT by introducing a non-mixture cure rate model and a smooth hazard function.
While the aforementioned schedule-finding designs are useful, it is obvious that a better design would simultaneously optimize the dose and schedule. For this, Braun et al. (2007) http://biostats.bepress.com/umichbiostat/paper93 developed the first design for dose-schedule-finding by extending the work of Braun et al. (2004) to incorporate different triangular hazard functions for each dose. However, as noted by Liu and Braun (2009) , the method of Braun et al. (2004) can be inflexible mainly due to its computational difficulty, the finite support of the triangular hazard function and the difficulties with including patient-level or administration-level covariates.
Thus, the first contribution of our current work is to generalize the methods of Liu and Braun (2009) to simultaneously optimize the dose and schedule assigned to each patient.
Specifically, we extend their Bayesian non-mixture cure model by incorporating the peradministration dose as a covariate for modeling the cure fraction to allow for multiple dose levels. In addition, we derive a non-mixture cure rate model through a competing risks approach to accommodate multiple administrations one patient may receive.
A second limitation of existing model-based adaptive Phase I designs is that they only determine the assignment for the next patient or group of patients by using the most recent model estimates. What these designs fail to do is to re-examine the assignments of patients who are still receiving treatment and may benefit from a change to their assignment, such as a higher dose at the next administration or increasing the number of planned administrations at the current dose. It is important to introduce intra-patient dose and/or schedule reassignment when necessary, especially for the patients enrolled early in a trial since they are more likely to receive a suboptimal dose or schedule. Although the model of Braun et al. (2007) could allow the possibility that the patient's planned dose for each administration to be changed, both the benefit of intra-patient dose change and how to reassign intra-patient dose and/or schedules are areas that have not been studied. The second contribution of our work is to adaptively optimize the dose and schedule assignments both among patients and within patients. While new patients are given the most recent maximum-tolerated dose-schedule combination (MTC) estimate, our approach also reevaluates the estimated DLT rate for the current assignment of each enrolled patient and
Hosted by The Berkeley Electronic Press automatically determines whether dose-schedule reassignment is needed. Patient accrual, data monitoring, and outcome-adaptive decision making are done continuously throughout the trial under a Bayesian formulation. We describe the probability model and the doseschedule-finding algorithm in Section 2, and we illustrate the proposed design in the context of a real trial and present a simulation study in Section 3. We conclude with a brief discussion in Section 4.
PROBABILITY MODEL

Preliminary Notation
Typical dose-schedule finding trials aim to find the MTC within a J × K matrix consisting of J per-administration doses and K nested schedules. We denote the administration times The number of subjects enrolled by the end of the trial is N and each subject will be followed up to the maximum follow-up time ω, which is determined by the clinical investigators and is a clinically meaningful duration of time that is sufficiently late enough to observe DLTs attributed to the longest schedule. A target DLT rate η is also elicited from clinicians and is defined as the targeted probability of cumulative toxicity by ω.
http://biostats.bepress.com/umichbiostat/paper93
j and s (k) represent the combinations of doses and schedule that are possible assignments to each patient as they enter the study. In contrast, at any point in the study, the actual number of administrations and the dose at each administration for each patient may differ from each of those possible combinations. To make this concept distinct, we let Let W i denote the study time when patient i enters the trial and we define W 1 = 0, which is the starting time of the trial. We further define Y i as the study time when patient i experiences a DLT. We will observe a DLT for patient i if W i < Y i W i + ω; otherwise, patient i will complete their follow-up without DLT being observed for the purposes of the study. At any study time t ∈ [W i , W i + ω], the follow-up time for patient i is U i = min(t, Y i ) − W i and the follow-up time for administration l of patient i is ν i,l = U i − s i,l , 1 l m k for a certain k determined by the schedule assigned to patient i. If patient i
has not yet experienced a DLT, i.e., t < Y i , we define the indicator of censoring C i = 0.
Once DLT is observed, C i = 1.
Model for Time-to-DLT After a Single Administration
As noted by Liu and Braun (2009) , a significant proportion of patients are "cured," i.e. never experience DLTs after a single administration. Thus, they chose to model the time-to-DLT for a single administration using a non-mixture cure model. Specifically, we take a standard cumulative distribution function F (ν|φ) with parameters φ, with a corresponding density function f (ν|φ), and scale F (ν|φ) by a parameter θ > 0 to create the respective survival and hazard functions S(ν|θ, φ) = exp[−θF (ν|φ)] and g(ν|φ, θ) = θf (ν|φ). We adopt S(ν|θ, φ)
as the probability of no DLT by follow-up time ν after a single administration and interpret θ as a cure rate parameter because the cure fraction S(∞) = exp(−θ) is determined solely
Hosted by The Berkeley Electronic Press by θ. The Time-to-Event CRM (TITE-CRM) of Cheung and Chappell (2000) for traditional dose-finding can be viewed as a mixture cure model for the time-to-DLT, as outlined in Braun (2005) . However, we have chosen to use a non-mixture cure rate model instead of a mixture cure model because the latter does not have a proportional hazards structure and is less feasible for Bayesian computations (Chen, Ibrahim, and Sinha 1999; Tsodikov, Ibrahim, and Yakovlev 2003) .
However, the non-mixture cure model used by Liu and Braun (2009) must be extended to allow the cure fraction to vary by dose. To that end, we model the cure rate fraction for administration l of patient i as log(
Note that we exponentiate β 1 > 0 to ensure that the probability of DLT after a single administration increases with dose. As a result, the respective hazard and survival
In order to fully specify the time-to-DLT after a single administration, we need to chose a specific form for f (ν i,l |φ). As recommended by Liu and Braun (2009) , we use a two-
Such a choice has biologic appeal because the resulting hazard function increases with time to a certain time point and then attenuates afterward, as was suggested by clinical investigators in our application. Mathematically, we expect the mode of the hazard function to exist at exp(γ/α)(1 − 1/α) 1/α , and we assume α > 1 so that the mode exists. We also considered modeling φ as a function of dose like we did for the cure fraction, but we found in simulations (results not shown) that this added level of complexity to our model offered no benefit to the performance of our design. In addition, such a model would eliminate the proportional hazards structure of our model.
Model for Time-to-DLT After Multiple Administrations
We employ a competing risks cure rate model by treating y i,l , the time to the DLT after administration l of patient i, as a latent variable to incorporate the multiple administrations received by each patient. The study time when patient i experiences a DLT is then defined as the random variable
Therefore, under the assumption of independence of y i,1 , . . . , y i,m i , the survival function for patient i at study
and the density function is given by
where
the follow-up time for administration l of patient i. The hazard function at study time t is given by h i (t; |β, φ,
, which indicates the cumulative effect of multiple administrations.
The assumption that the times-to-DLT after each administration, y i,1 , . . . , y i,m i , are independent for the m i administrations of the same patient i might not hold, although the actual amount of correlation is not testable (Tsiatis 1975) . A more general model could be based on an Archimedean copula-type model, which can also be regarded as a frailty model with a cure fraction (Hougaard 2000) . For example, the above survival function could be generalized to
which is a Gumbel copula model with a correlation parameter ξ, in which ξ = 0 indicates independent DLT times. In this paper, we will assume independence for our model since it is simple and we feel that copula models could possibly impose strong and untestable assumptions on the correlation structure of DLT times.
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Another assumption of our model is the log-linearity for modeling the relationship between the cure parameter θ and dose. This assumption could be relaxed by either adding more parameters in the model to allow for the non-linearity or using a Bayesian model averaging approach among differing models (Raftery, Madigan, and Hoeting 1997; Ying and Yuan 2009 ). However, we feel that the log-linear model should be adequate in many settings for identifying the MTC since the sample size is usually small in Phase I trials and the overall model fit is not our primary interest (O'Quigley et al. 1990) .
From this notation, the likelihood function can be derived with ease. By study time t which is determined independently of time-to-DLT, we denote the number of patients currently in the study as n and for each enrolled patient, we know s i and d i , the respective time and dose for each administration, ν i = {ν i,1 , . . . , ν i,m i }, the follow-up times for each administration, and C i , which indicates whether or not a DLT was observed for patient i.
Based on the above information, Equations (1) and (2), the likelihood is given by
After determining the prior distributions for β and φ, we can compute posterior quantities via adaptive Markov Chain Monte Carlo (MCMC) methods (Rosenthal 2007) . Those posterior quantities will be used to identify the dose-schedule assignment for a new patient and a possibly new dose-schedule assignment for an existing patient as described in Section 2.5.
Establishing Prior Distributions
For the two parameters of the cure fraction, β, we assign independent Gaussian distributions with prior mean and prior variance (µ 0 , σ 2 0 ) for β 0 and (µ 1 , σ 2 1 ) for β 1 . In order to determine values for the prior means µ 0 and µ 1 , we ask the investigators to provide the "skeleton" P, which is a J × K matrix of a priori estimates of the DLT rates by ω for all doseschedule combinations, in which element (j, k), denoted P jk , corresponds to the combination http://biostats.bepress.com/umichbiostat/paper93 of dose j and schedule k. We then fit the linear regression model log(− log[1 For the two parameters of the hazard, φ = (α, γ), we have chosen to make α fixed to maintain a parsimonious model and limit the number of parameters to estimate. In addition, preliminary simulations (results not shown) indicated that there was no meaningful change in operating characteristics when assigning a prior distribution to α. However, because the mode of the hazard for a single administration monotonically increases with γ, estimation of γ is important to the performance our algorithm. Therefore, we assign a Gaussian prior distribution for γ with mean µ γ and variance σ 2 γ . To determine values for α and µ γ , we apply the method outlined in Liu and Braun (2009) for each dose and calculate the average.
If the resulting value for α < 1, we set α = 1.01, so that the mode exists.
It is important to carefully calibrate the prior variances σ The prior variances should not be too small, otherwise the prior information dominates the trial. However, they cannot be too large either since we hope to incorporate the prior information for possibly more accurate estimation. We recommend calibrating the prior variances through simulations using a few different skeletons and prior variances. The prior variance that is the most insensitive to skeletons and leads to the best operating characteristics will be used for a real trial. We present an example of variance calibration related to the simulations of Section 3..
Algorithm for Adaptive Assignments for New Patients and Reassignments for Enrolled Patients
The algorithm for assigning a dose-schedule combination to a new patient i is similar to that used in the CRM and many other Phase I designs. When a new patient enters the study, for every combination of a dose j and a schedule k, we computep jk = 1 −
, the estimated DLT rate by the maximum follow-up time ω, wherê φ andβ are the respective posterior means of φ and β. Given a desired DLT rate η, the dose-schedule combination that minimizes the distance |p jk − η|, which we denote (j * , k * ) is assigned to the next patient, subject to one restriction. Both j * and k * cannot simultaneously be respectively more than one dose higher than j i−1 , the dose assigned to the most recently enrolled patient, and k i−1 , the schedule assigned to the most recently enrolled patient. Even though we use a "no-skipping" rule for dose-schedule escalation among successive patients, there is no such rule when it comes to de-escalation. We place no restriction on escalation of dose and schedule within a patient, which some may view as overly aggressive, but in the simulation results presented in Section 3.3, we see no evidence of a higher than desired rate of DLTs. We also ran simulations in which the among-patient restriction on escalation to also applied within-patient (results not shown). We saw little change to the results presented in Table 4 , except that patient assignments to acceptable combinations tended to lessen with the restriction than without it. Lastly, if necessary, we could implement a stopping rule to terminate a trial when the accumulated data indicates that all combination of doses and schedules are overly toxic. One such rule would be to terminate the trial if the estimated DLT rate for the lowest combination is above a threshold, for instance, η + 0.1.
We emphasize that reassignment of dose and/or schedule does not apply to patients who have experienced DLT, nor to those who finished their originally assigned treatment, nor those whose treatment was terminated early. For the remaining n * n patients who are still planning to receive additional administrations, we computep = 1
which is the estimated DLT rate of the administrations received so far by patient = 1, 2, . . . n * . We immediately terminate the treatment of any patient for whomp η +0.1, as they have already received a combination that appears to be overly toxic and further http://biostats.bepress.com/umichbiostat/paper93 treatment would be unethical. Once the treatment is terminated, no additional administrations will be given to the patient but this patient is still under follow-up until a DLT occurs or the maximum follow-up time ω is reached.
For each of the remaining patients for whomp < η + 0.1, we need to consider how many more administrations might be given and which dose would be given at each of those administrations. Specifically, if m is the number of administrations received so far, we compute δ k = (m k − m ), for each schedule k, including the schedule to which the patient was originally assigned. Among all schedules with δ k > 0, let s
+ denote the remaining administration times for schedule k that could still be assigned to patient . We consider the combination of each s
+ with each dose j and let d
+ denote the remaining dose assignments, which is a vector of δ k elements each with the value d j . We then compute
+ ]), which is the probability of DLT by ω for patient for each of these possible reassignments appended to what he has already received.
We will reassign patient according to whichever P (jk) is closest to the targeted DLT rate, η. We emphasize again that one of the possible "reassignments" is simply the assignment currently belonging to patient .
To clarify our notation, we consider a hypothetical study of J = 3 doses and K = 5 schedules in which schedule k is comprised of k consecutive (5+, 24−) courses as described in Section 2.1. Imagine that a new patient is to be enrolled in the study and that we have an enrolled patient who was assigned to schedule 3, has not yet experienced a DLT, and has respective administration times and doses for each administration s = , 1, 2, 3, 4, 28, 29, 30, 31, 32, 56, 57} and d = {8, 8, 8, 8, 8, 16, 16, 16, 16, 16, 32 , 32} mg/m 2 .
{0
As each schedule had a total of five planned administrations, we see that patient has completed two courses and has three administrations remaining in her third course. Assuming that the treatment received so far does not have an estimated DLT rate 10 points above the target, Table 1 delineates the nine possible remaining assignments that could now be given to patient . Whichever of these nine combinations, when appended to s and d , leads to an estimated DLT rate by ω closest to the target DLT rate is the reassignment given to patient .
[ Table 1 about here.] This example emphasizes the fact that we attempt to keep the dose constant within a patient as much as possible, i.e. each administration for a patient will be at the same dose until a reassignment occurs. Thus, the hypothetical patient described above had already received two previous changes to her assignment, as her dose was increased from 8 mg/m 2 , then to 16 mg/m 2 , and then again to 32 mg/m 2 . Of course one could consider a setting in which the best treatment plan would be contrary to this, i.e. perhaps alternating back-andforth between two doses. However, such a treatment plan, or one that considers any of the J doses at each administration period would be infeasible in practice and would likely lead to treatment errors if the treatment plans assigned to several patients were all different and impossible to remember.
Furthermore, we have chosen to only consider reassignments when a new patient is enrolled. This certainly is not the only benchmark at which we might consider reassigning patients. For example, we might instead (or also) re-evaluate the data collected so far each time a patient completes their follow-up, either by reaching ω without a DLT or experiencing a DLT sometime before ω. Or we could re-evaluate the data each time a patient completes a course, thereby allowing a course-by-course evaluation for every patient. And if we truly wanted to optimize the treatment of every patient in the study, it would seem most sensible to evaluate each patient after every single administration. However, most of these alternate approaches are unrealistic in practice as the frequency of the necessary computations would become administratively impossible. On the opposite end of the spectrum, we could administratively set times, i.e. every three months, when we might consider reassignments that have nothing to do with patient outcomes but makes the process of re-assignment known before the trial begins. However, we feel our approach of re-evaluating assignments when each new patient is enrolled is a good compromise between optimizing the treatment of each patient as much as possible and maintaining a feasible level of computation.
Conduct of the Trial
We plan on enrolling a maximum of N patients in the trial, and each patient will be followed for ω days after enrollment. The first patient is enrolled at study time t = 0 and is assigned to the shortest schedule (k = 1) with the lowest dose (j = 1). When patient i = 2, . . . , N is to be enrolled in the study at study time t, we perform the following steps:
(1) Place each enrolled patient i = 1, 2, . . . i into one of two groups, either those without DLT or those with DLT;
(2) For patients without DLT, record:
, the length of follow-up for a patient enrolled at study time
(3) For patients with DLT, record:
which Y i is the study time at which DLT occurred;
(4) For all enrolled patients, record s i , the vector of times of each administration received, and d i , the vector of doses given at each administration;
(5) Use the information recorded from (2)-(4) above to compute the likelihood given in Equation (3). Specifically, patients without DLT will contribute an amount given in Equation (1) and patients with DLT will contribute an amount given in Equation (2);
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(7) For all enrolled patients, apply the methods described in Section 2.5 to determine whether to assign a new dose and/or schedule or terminate their treatment altogether;
(8) Determine the dose and schedule assignment for patient i using the methods described in Section 2.5;
(9) Once all N patients have been enrolled, use all accumulated data to compute final posterior estimates of the DLT rates of each dose and schedule combination and select the combination with estimated DLT rate closest to η as the optimal combinations 3. APPLICATION
Simulation Design
We study our design in simulations based upon the motivating example of Braun et al. and m 4 = 20, for a total of 12 combinations. A course consists of five daily consecutive administrations followed by 28 days of rest as described in the example in Section 2.1, and schedule k consists of k consecutive courses. Investigators would like to determine which of the 12 combinations have a DLT rate close to η = 0.30. A maximum of N = 60 patients will be enrolled. The maximum follow-up time for each patient is ω = 116 days. We consider the dose-schedule combinations with DLT rates of η ± 0.10 to be acceptable choices of the MTC, since a small deviation from η is acceptable for the investigators (Braun et al. 2007 ).
We consider two skeletons that we feel would reflect those most commonly used in practice. Skeleton 1 specifies the a priori MTC to exist at middle combinations whereas Skeleton 2 specifies the highest combinations as the a priori MTC. each skeleton, we used the methods described in Section 2.5 to calculate the prior means. [ Table 2 about here.]
We examined our approach in 15 different scenarios that are summarized in Table 3 . The true DLT rates of every combination of dose and schedule were created from an approach that we now describe and that is different from the model described in Section 2.3. We let p d j denote the probability of DLT by ω after a single administration of dose j = 1, 2, 3, and we let n j denote the number of administrations of dose j received. Then, for a treatment schedule of n 1 , n 2 , and n 3 administrations of doses 1, 2, and 3, respectively, regardless of their order, we denote the actual probability of DLT by time ω as P true (d 1 , d 2 , d 3 , n 1 , n 2 , n 3 ).
[ Table 3 about here.]
In scenarios 1-4, we assume that all administrations have independent effects (which is also the assumption used in our model), i.e.
in which q d j = 1− p d j . In scenarios 5-10, we assume that all administrations have correlated effects modeled via a Gumbel copula, i.e.
and is the same as Equation (4) when the correlation parameter ξ = 1. In scenarios 11-15, we assume that all administrations have correlated effects modeled via a Frank copula, i.e.
and is the same as Equation (4) when ξ → 0.
The value of ξ used in each of scenarios 5-15 is shown in the last column of Table 3 and the actual values of p d1 , p d2 , and p d3 used in each of the fifteen scenarios are shown in the column labeled "p d " in Table 3 . Although Table 3 We simulated patients to have exponentially distributed inter-arrival times with a mean of two weeks, and we divided all the follow-up times by 10 to achieve better numeric stability for our model. When a new patient is enrolled, an interim analysis is performed in which a single chain of 6, 000 samples, after a burn-in of 4, 000 samples, is drawn from the posterior distribution for each parameter. These posterior draws are then used to determine the dose and schedule assigned to the new patient as well as any dose and/or schedule reassignments for each currently enrolled patient still being followed. We then simulate for each a binary indicator of DLT using Equation (4), (5), or (6) depending upon the scenario examined. If a patient is simulated to have a DLT, the time of the DLT is drawn uniformly from the interval [4 + 24(k − 1), 4 + 24k] under their assigned schedule k, which also implies that http://biostats.bepress.com/umichbiostat/paper93 all possible DLTs occur by ω = 116 days. We did perform simulations of our design using our assumed model to simulate DLTs and came to similar final conclusions, and we have omitted those results for brevity.
We compared the performance of our approach that allows for patient reassignment (Design A) with the traditional approach that does not allow for patient reassignment (Design B). We evaluated the performance of both approaches in all 15 scenarios by comparing the correct selection frequency at the end of the study, the mean proportion of patients assigned to each dose-schedule combination and the mean proportion of patients who experienced DLTs. We performed 1, 000 simulations in each scenario; our computer code is available upon request.
Calibration of Prior Variance
To achieve good operating characteristics, we first calibrated the prior standard deviations via simulation. We let σ 1 , σ 2 and σ 3 have the same value σ to simplify the calibration process. The prior standard deviation that performs best among σ = 1, 2, 5 would be used in the study. We certainly could have examined more values of σ, but felt that choosing among these three values was sufficient and any small deviations in performance with other possible values for σ were outweighed by the increased amount of simulation time required.
The first row of Figure 1 shows how the prior variance impacts the proportion of patients assigned to acceptable dose-schedule combinations in Design A using either skeleton 2 (upper left plot) or skeleton 1 (upper right plot). For both skeletons, the design using σ = 5 performs worse than using σ = 1 or σ = 2 in most of the 15 scenarios. However, from these two plots, it is not clear which among between σ = 1 and σ = 2 would be preferred. Therefore, the bottom two plots in Figure 1 attempt to assess the sensitivity of the results to the chosen skeleton when using σ = 2 (lower left plot) and σ = 1 (lower right plot). From these two plots, we see that there is greater variation in the results when using σ = 1 than σ = 2. We also performed similar analyses for the proportion of simulations in which acceptable dose-schedule combinations were selected at the end of the study, as well as repeating our calibration with Design B (no reassignment), and found little change in our conclusions. Therefore, we selected σ = 2 to be the prior standard deviation used in the study. And since our design is not sensitive to the skeletons when σ = 2, we have chosen to use Skeleton 2 in our study.
[ Figure 1 about here.] Table 4 contains a summary of the performance of both Design A (with reassignment) and Design B (without reassignment) in all 15 scenarios described in Table 3 . For each design, this summary is a series of seven columns. The first three columns describe the proportion of simulations in which the MTC selected at the end of the study had a DLT rate more than 10 points below the desired DLT rate η (column "L"), within 10 points of η (column "In"), or more than 10 points above η (column "H"). The next three columns have a similar interpretation related to the average percentage of dose-schedule assignments during the study. The seventh column, labeled "DLT" is the average of the proportion of observed DLTs among the 1,000 simulations. The summary for Design A contains an additional column, labeled "Rn", which is the average proportion of patients receiving at least one reassignment during the study.
Simulation Results
Overall, we are able to identify acceptable dose-schedule combinations at the end of the study in a majority of simulations in all 15 scenarios, whether or not reassignment is used. This is not surprising, as the primary goal of reassignment is to optimize the assignments of patients enrolled in the study, rather than improve the final decision at the end of the study. Scenarios 4, 8, 9, and 10 have the lowest percentages of identifying the MTC at an acceptable combination, which is partially explained by the fact that these scenarios have http://biostats.bepress.com/umichbiostat/paper93 only 1 or 2 acceptable combinations to choose from. These scenarios also have some of the largest values of MSE, indicating that the assumption of linearity in our model is suspect.
Nonetheless, we emphasize that all 15 scenarios have DLT rates that come from models that are different from our assumed model, so that our approach works well even when the model is misspecified.
With regard to patient assignments during the study, we see that including reassignment leads to a higher proportion of patients assigned to acceptable combinations than without reassignment. For example, in scenario 4, Design A assigned 55% of the patients to acceptable combinations, compared with only 30% for Design B, and the corresponding percentages in scenario 10 are 52% and 27%, respectively. Moreover, in all 15 scenarios, the average DLT rate when using reassignment is never more than the average observed DLT rate without reassignment and is always close to the desired DLT rate. The one possible exception is scenario 7, which had an average observed DLT rate of 0.38, which might seem higher than desired. However, in Table 3 we see that all combinations in scenario 7 have DLT rates of 0.30 or more, so it is not surprising that a higher than desired DLT rate was observed.
With regard to patient reassignment, we see that the proportion of reassignments varied among the 15 scenarios from 0.20 in scenario 7 to 0.69 in scenario 4. The lowest rates of reassignment were seen in scenarios 1, 7 and 9; a common feature of these three scenarios is that most of the dose-schedule combinations are either toxic or inefficacious. Rates of reassignment above 0.60 were seen in scenarios 4, 8, 10, 11, and 15. Although the explanation for the high rate of reassignment is not immediately obvious, it may be partially due to the fact that acceptable combinations in these scenarios appear with longer schedules of the highest dose, with even longer schedules then becoming overly toxic. This is contrasted to scenario 1, which has a much lower rate of reassignment because there are no overly toxic combinations.
[ Table 4 about here.]
Recall that we found that using a value of σ = 2 for the prior variances of the model parameters was insensitive to the skeleton used. To confirm this statement, we do not present the results when using Skeleton 1 in a tabular format like that of Table 4 . Instead, Figure 2 contains a visual summary of the percentage of simulations in which the MTC was selected at an acceptable combination (left plot) and the percentage of patients assigned to acceptable combinations (right plot) in each of the 15 scenarios. As we found in Table   4 , we are able to identify the MTC well whether or not reassignment is allowed, but that inclusion of reassignment greatly improves the treatment assignment of patients enrolled in the study.
[ Figure 2 about here.]
DISCUSSION
In this work, we have contributed to the existing literature on the design of dose-and schedule-finding studies by first expanding the schedule-finding model used by Liu and Braun (2009) And though we introduce our design in the setting of dose-schedule finding studies, our methods could be easily applied to other settings. If the schedule were fixed while the dose varied, our design would be similar to the TITE-CRM in which the weight function would be determined by the functional form of the hazard function of a single administration in our model. Our methods are also applicable to trials studying non-nested schedules like that in Li, Bekele, and Cook (2008) , although since there is no natural order for non-nested schedules, our approach could be modified to only allow reassignment of doses but not schedules. In Phase I/II studies, one can easily adapt our method to the work of Yuan and Yin (2009) to model late-onset toxicity/efficacy and introduce intra-patient dose/schedule changes. Similar modifications could be made to apply our approach to trials of combinations of two agents by specifying the hazard function of the toxicity or efficacy after a single administration to be a function of doses of both agents. However, the model that takes account of the joint distribution of toxicity and efficacy as a function of possibly multiple doses is not immediately obvious and should be carefully chosen. Lastly, even in a trial with a fixed schedule and multiple doses, one might still want to add more administrations later to patients with neither toxicity nor efficacy (Fan and Wang 2007) in efforts of increasing the probability of efficacy. Our model could be used to determine the number of additional administrations and the dose for each administration adaptively. Table 4 . Simulation results for Design A and B using prior standard deviation σ = 2 and Skeleton 2. For each design, columns "Selection" gives the percentage of identifying three categories of combinations as the MTC: unacceptable inefficacious combinations ("L") ; acceptable combinations ("In") and too toxic combinations ("H"). For each design, columns "Assignment" gives the mean proportion of patients assigned to the three categories, columns "DLT" give the mean proportion of patients who experienced DLTs and the column "Rn" gives the mean proportion of patients whose experienced dose or schedule reassignment. 
